Tag: Dr. William O’Neill


Dr. Bill O’Neill explains the concept of cardioprotection

What is Cardioprotection? Dr. Bill O’Neill of Henry Ford Health System and co-principle investigator of the FDA STEMI-DTU safety and feasibility RCT, discusses the concept of cardioprotection. Cardioprotection is a cellular response to protect the myocardium from suffering irreversible injury.   IMP-449 Subscribe, or join the conversation by following us on Twitter: @ProtectedPCI To learn more about … Continue reading “Dr. Bill O’Neill explains the concept of cardioprotection”

National Cardiogenic Shock Initiative: 1 Year Later

Video Chapters: The Impact of The Cardiogenic Shock Initiative (NCSI): One Year Later William O’Neill, MD Advances in the Treatment of Cardiovascular Disease in Women: PCI, MI, Shock, Myocarditis, SCAD, and Post-partum Cardiomyopathy Cindy Grines, MD Understanding the Importance of Ventricular Unloading in Management of AMI and Cardiogenic Shock Navin Kapur, MD Subscribe, or join the … Continue reading “National Cardiogenic Shock Initiative: 1 Year Later”

Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device

Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) database. The clinical publication highlights best practice protocols based on real-world evidence that is showing improved outcomes in cardiogenic shock. This clinical evidence is derived from Abiomed’s observational , commercial IQ database. In patients with AMICS receiving … Continue reading “Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device”

Protected PCI: Current Data and Best Practices in High-Risk Patients

In this roundtable discussion, Dr. John Lasala of Washington University in St. Louis interviews Dr. Bill O’Neill (Henry Ford Hospital, Detroit, MI), Dr. Bill Lombardi (University of Washington, Seattle, WA), and Dr. Jeff Moses (Columbia University, New York, NY) on the current data regarding high-risk patients undergoing Protected PCI. During this interview, Dr. Moses provides … Continue reading “Protected PCI: Current Data and Best Practices in High-Risk Patients”

Hemodynamic Benefits of Impella RP® Heart Pump for Right Heart Failure

Dr. William O’Neill and Dr. Mark Anderson, co-principle investigators of the RECOVER-RIGHT clinical trial, and Dr. Seth Bilazarian discuss the hemodynamic benefits of using the Impella RP® heart pump for right heart failure. The Impella RP® is the first and only percutaneous heart pump approved by the FDA as safe and effective for acute right … Continue reading “Hemodynamic Benefits of Impella RP® Heart Pump for Right Heart Failure”

Dr. Bill O’Neill Discusses Recovery Time from RV and LV Shock with Impella RP® Support

In this physician Q&A session, Dr. Bill O’Neill discusses recovery considerations as well as time to recovery following Impella RP® support for right ventricular (RV) and left ventricular shock. In this video, Dr. O’Neill also describes the rapid recovery (<24 hours) of patients with acute myocardial infarction receiving the Impella RP®. In addition, Dr. O’Neill … Continue reading “Dr. Bill O’Neill Discusses Recovery Time from RV and LV Shock with Impella RP® Support”

IMPRESS in Severe Shock Trial: Looking Closer at the Data

For patients with cardiogenic shock (CS), intra-aortic balloon pump (IABP) had been an important tool for maintaining patients and improving survival after percutaneous coronary intervention (PCI). Randomized controlled trials, however, have found very little evidence to support the notion that IABP is helpful for reducing mortality or improving hemodynamics for patients with CS.1,2 The Impella® … Continue reading “IMPRESS in Severe Shock Trial: Looking Closer at the Data”

Detroit Cardiogenic Shock Initiative: Initial Results

Data presented by Dr. William O’Neill of Henry Ford Hospital System at the 66th Annual Scientific Session of the American College of Cardiology also included new data from the Detroit Cardiogenic Shock Initiative (DCSI), an unprecedented collaboration between five heart hospitals in Detroit, with the goal of determining whether outcomes in cardiogenic shock can be … Continue reading “Detroit Cardiogenic Shock Initiative: Initial Results”

Impella® Quality Assurance Program: Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery

  Data from Abiomed’s Impella® Quality (IQ) Assurance Program, which includes the IQ Database and cVAD Registry, was presented today as late-breaking Featured Clinical Research by Dr. William O’Neill of Henry Ford Hospital System at the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington, D.C. These data were derived from the IQ Database … Continue reading “Impella® Quality Assurance Program: Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery”